N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B

1. A compound of formula I:

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof

wherein:

L 1 is straight or branched C 1 -C 5 alkylene substituted with OH;

each R 10 and R 10 ′ is independently selected from the group consisting of H;

C 1 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of OH, O—C 1 -C 5 alkyl, OPO 3 −2 M 2 , OP(O)(OH) 2 , OC(O) alkyl, and OC(O)O-alkyl where M is a monovalent metal cation; and

cycloalkyl optionally substituted with one or more substituents selected from the group consisting of OH and O—C 1 -C 5 alkyl provided that no more than one oxygen is attached to any carbon; or R 10 and R 10 ′, together with the nitrogen to which they are attached, may form a heterocycle selected from the group consisting of oxetanyl, azetadinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, and homotropanyl;

R 1 is cycloalkyl, aryl, or heteroaryl, any of which optionally substituted with one or more substituents selected from the group consisting of OH, CN, halogen, —C 1 -C 6 alkylaryl, —O—C 1 -C 6 alkylaryl, O—R 10 , OPO 3 −2 M 2 , OP(O)(OH) 2 , SH, S—R 10 , C 1 -C 5 alkyl, branched alkyl, NH 2 , NHR 10 , NHS(O) 2 R 10 , N(R 10 )(R 10 ′), and NHCOR 10 where M is a monovalent metal cation;

X is selected from O, S, —S(O)—, and —S(O) 2 —;

Y and Y′ are independently H, halogen, or C 1 -C 5 alkyl;

L 2 is a bond, —(CH 2 ) n — or —(CHR 11 ) n —;

each R 11 is independently selected from the group consisting of H, —C 1 -C 5 alkylenyl-, —CO—C 1 -C 5 alkylenyl-, and -alkylenyl-CO-alkylenyl-;

R 2 is phenyl, naphthyl, heteroaryl or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents selected from the group consisting of halogen, OH, C 1 -C 6 alkyl, OR 10 , CN, NH 2 , NHR 10 , N(R 10 )(R 10 ′), -nitro, SH, SR 10 , SOR 10 , SO 2 R 10 , SO 2 NHR 10 , SO 2 N(R 10 )(R 10 ′), CONH 2 , CONR 10 , and CON(R 10 )(R 10 ′); and

n is 1, 2, or 3;

wherein cycloalkyl is a monocyclic saturated carbon ring containing 3-18 carbon atoms, and

wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic radical of 5 to 10 ring atoms and containing one or more ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, and when containing two fused rings, the aryl groups may have an unsaturated or partially saturated ring fused with a fully saturated ring.

2. The compound of claim 1 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein L 2 is a bond and R 2 is phenyl optionally substituted with one or more halogen, OH, OR 10 , CN, NH 2 , NHR 10 , N(R 10 )(R 10 ′), SH, SR 10 , SOR 10 , SO 2 R 10 , SO 2 NHR 10 , SO 2 N(R 10 )(R 10 ′), CONH 2 , CONR 10 , CON(R 10 )(R 10 ′).

3. The compound of claim 2 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein X is O.

4. The compound of claim 2 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R 1 is aryl or heteroaryl each of which is substituted with one or more substituents selected from the group consisting of OH, halogen, OR 10 , SH, SR 10 , NH 2 , NHR 10 and NHCOR 10 .

5. The compound of claim 2 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein Y and Y′ are hydrogen.

6. A compound of formula Ia:

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof

wherein:

A, B, C, D, and E are independently N or CR x ;

is an optional double bond;

X is CH or C;

U is OH or O;

Y and Y′ are independently H, halogen, or C1-C6 alkyl;

R 3 is H;

each R x is independently H, C 1 -C 6 alkyl, halogen, —OH, —NHS(O) 2 R 10 , or —OC 1 -C 6 alkyl;

R 10 is selected from the group consisting of H; C 1 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of OH, O—C 1 -C 5 alkyl, OPO 3 −2 M 2 , OP(O)(OH) 2 , OC(O)alkyl, and OC(O)O-alkyl where M is a monovalent metal cation; and cycloalkyl optionally substituted with one or more substituents selected from the group consisting of OH and O—C 1 -C 5 alkyl provided that no more than one oxygen is attached to any carbon; and

L 2 is a bond or (CH 2 ) n , wherein n is 1 or 2.

7. A compound of claim 1 , or a pharmaceutically acceptable salt, tautomer, orstereoisomer thereof, selected from the group consisting of:

8. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable carrier.

9. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, which is

10. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, which is

11. A compound of the following structure:

or a pharmaceutically acceptable salt thereof.

12. A compound of the following structure:

or a pharmaceutically acceptable salt thereof.

13. A compound of the following structure:

or a pharmaceutically acceptable salt thereof.

14. A compound of the following structure:

or a pharmaceutically acceptable salt thereof.

15. A compound of claim 6 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, selected from the group consisting of:

16. A compound, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, selected from the group consisting of:

17. A pharmaceutical composition comprising a compound of claim 6 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising a compound of claim 11 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising a compound of claim 12 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising a compound of claim 13 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising a compound of claim 14 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising a compound of claim 16 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.